BG108164A - Glyt-1 inhibitors - Google Patents

Glyt-1 inhibitors

Info

Publication number
BG108164A
BG108164A BG108164A BG10816403A BG108164A BG 108164 A BG108164 A BG 108164A BG 108164 A BG108164 A BG 108164A BG 10816403 A BG10816403 A BG 10816403A BG 108164 A BG108164 A BG 108164A
Authority
BG
Bulgaria
Prior art keywords
glyt
inhibitors
neurological
pharmaceutical
compound
Prior art date
Application number
BG108164A
Other languages
Bulgarian (bg)
English (en)
Inventor
Ian Egle
William Delaney
Zhaoqing Wang
Richard Shumacher
Allen T. Hopper
Ashok Tehim
Shawn Maddaford
Original Assignee
Allelix Neuroscience,Inc.
Nps Allelix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23026417&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG108164(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allelix Neuroscience,Inc., Nps Allelix Corp filed Critical Allelix Neuroscience,Inc.
Publication of BG108164A publication Critical patent/BG108164A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
BG108164A 2001-02-16 2003-09-09 Glyt-1 inhibitors BG108164A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26924101P 2001-02-16 2001-02-16
PCT/CA2002/000176 WO2002066456A2 (en) 2001-02-16 2002-02-15 Thiophene substituted amine derivatives as glyt-1 inhibitors

Publications (1)

Publication Number Publication Date
BG108164A true BG108164A (en) 2004-07-30

Family

ID=23026417

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108164A BG108164A (en) 2001-02-16 2003-09-09 Glyt-1 inhibitors

Country Status (31)

Country Link
US (1) US6667336B2 (xx)
EP (1) EP1368336B9 (xx)
JP (2) JP2004523548A (xx)
KR (1) KR100900020B1 (xx)
CN (1) CN1219776C (xx)
AT (1) ATE327986T1 (xx)
AU (1) AU2002235682C1 (xx)
BG (1) BG108164A (xx)
BR (1) BR0207307A (xx)
CA (1) CA2438367A1 (xx)
CY (1) CY1105529T1 (xx)
CZ (1) CZ20032503A3 (xx)
DE (1) DE60211866T2 (xx)
DK (1) DK1368336T3 (xx)
EA (1) EA006636B1 (xx)
EE (1) EE05329B1 (xx)
ES (1) ES2266446T3 (xx)
HK (1) HK1061025A1 (xx)
HR (1) HRP20030696A2 (xx)
HU (1) HUP0303185A3 (xx)
IL (1) IL157194A (xx)
MX (1) MXPA03007309A (xx)
NO (1) NO329038B1 (xx)
NZ (1) NZ527695A (xx)
PL (1) PL365024A1 (xx)
PT (1) PT1368336E (xx)
SI (1) SI1368336T1 (xx)
SK (1) SK287304B6 (xx)
UA (1) UA75114C2 (xx)
WO (1) WO2002066456A2 (xx)
ZA (1) ZA200307201B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191165B1 (en) * 1996-05-31 2001-02-20 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
DK1830833T3 (da) * 2004-12-16 2010-05-17 Janssen Pharmaceutica Nv Kombination af en glycintransportør (GLyT1) inhibitor og et antipsykotikum til behandling af symptomer på schizofreni samt dens fremstilling og anvendelse deraf
US20090253918A1 (en) * 2006-10-02 2009-10-08 Janssen Pharmaceuticals, N.V. Novel intermediate for glyt1 inhibitor
WO2008065500A2 (en) * 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
CN103374057B (zh) * 2012-04-16 2015-08-19 中国医药集团总公司四川抗菌素工业研究所 一种对甘氨酸转运子具有抑制活性的化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3050800C2 (xx) 1979-03-22 1989-06-22 Continental Pharma Inc., Bruessel/Bruxelles, Be
BE885303A (fr) 1980-09-19 1981-03-19 Continental Pharma Glycinamides
US4383999A (en) 1981-05-26 1983-05-17 Smithkline Beckman Corporation Inhibition of GABA uptake by N-substituted azaheterocyclic carboxylic acids and their esters
AU552050B2 (en) 1981-05-26 1986-05-22 Smithkline Beckman Corporation N-substituted azeheterocyclic carboxylic acids and their esters
US4514414A (en) 1982-10-25 1985-04-30 Smithkline Beckman Corporation N-Substituted pyrrolidineacetic acids and their esters
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
US4772615A (en) 1985-11-08 1988-09-20 Warner-Lambert Company Various N-substituted 3-piperidine carboxylic acids or N-substituted 3-pyridinecarboxylic acids and derivatives thereof
FI864246A (fi) 1985-11-08 1987-05-09 Warner Lambert Co N-substituerade 3-piperidin- eller 3-pyridinkarboxylsyror samt deras derivat.
EP0231996B1 (en) 1986-01-07 1993-10-06 Novo Nordisk A/S Novel amino acid derivatives
JPH02129158A (ja) 1988-11-07 1990-05-17 Nippon Steel Corp 光学活性なグリシン誘導体及びその製造方法
IE913279A1 (en) * 1990-09-26 1992-04-08 Astra Ab (2-Thienyl)alkylamine Derivatives Having Neuroprotective¹Properties
ES2036926B1 (es) 1991-08-08 1994-01-16 Uriach & Cia Sa J "procedimiento para la obtencion de derivados de la (2-alquil-3-piridil)metilpiperazina".
DK0871440T3 (da) 1995-12-07 2006-07-10 Daniel C Javitt Behandling af negative og kognitive symptomer på skizofreni med glycinoptagelsesantagonister
SK285854B6 (sk) * 1996-05-31 2007-09-06 Allelix Neuroscience Inc. Substituovaný amín, spôsoby jeho prípravy a použitie, farmaceutický prostriedok a jeho použitie
US6191165B1 (en) 1996-05-31 2001-02-20 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
DE69734215T2 (de) * 1996-07-22 2006-06-29 Novo Nordisk A/S Verbindungen mit Wachstumshormon-freisetzenden Eigenschaften
DE69819206T2 (de) * 1998-01-09 2004-04-15 Pfizer Inc. Matrixmetalloproteinaseinhibitoren
US6103743A (en) * 1999-08-06 2000-08-15 Allelix Neuroscience, Inc. Unsaturated amino acid derivatives

Also Published As

Publication number Publication date
CY1105529T1 (el) 2010-07-28
DK1368336T3 (da) 2006-10-02
EP1368336B1 (en) 2006-05-31
ATE327986T1 (de) 2006-06-15
CN1219776C (zh) 2005-09-21
EA006636B1 (ru) 2006-02-24
EA200300900A1 (ru) 2004-02-26
WO2002066456A2 (en) 2002-08-29
EE200300394A (et) 2003-12-15
CZ20032503A3 (cs) 2004-02-18
DE60211866T2 (de) 2007-06-14
NZ527695A (en) 2005-05-27
AU2002235682B2 (en) 2007-04-26
HRP20030696A2 (en) 2005-04-30
ES2266446T3 (es) 2007-03-01
DE60211866D1 (de) 2006-07-06
US20030176489A1 (en) 2003-09-18
WO2002066456A3 (en) 2002-10-17
US6667336B2 (en) 2003-12-23
HUP0303185A2 (hu) 2003-12-29
IL157194A (en) 2006-12-31
UA75114C2 (en) 2006-03-15
NO20033634D0 (no) 2003-08-15
EP1368336A2 (en) 2003-12-10
PL365024A1 (en) 2004-12-27
JP2010059182A (ja) 2010-03-18
ZA200307201B (en) 2004-07-28
BR0207307A (pt) 2004-08-17
HK1061025A1 (en) 2004-09-03
NO329038B1 (no) 2010-08-02
HUP0303185A3 (en) 2008-12-29
SK287304B6 (sk) 2010-06-07
SI1368336T1 (sl) 2006-10-31
PT1368336E (pt) 2006-10-31
SK11442003A3 (sk) 2004-03-02
AU2002235682C1 (en) 2008-12-11
NO20033634L (no) 2003-10-08
MXPA03007309A (es) 2004-06-30
JP2004523548A (ja) 2004-08-05
CN1491221A (zh) 2004-04-21
EP1368336B9 (en) 2007-02-14
CA2438367A1 (en) 2002-08-29
EE05329B1 (et) 2010-08-16
KR100900020B1 (ko) 2009-06-01
KR20040028719A (ko) 2004-04-03

Similar Documents

Publication Publication Date Title
IL127244A0 (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
DE60329001D1 (en) 8-hydroxychinolinderivate
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
IL157320A0 (en) Rapid-onset medicament for the treatment of sexual dysfunction
MXPA03010761A (es) Combinaciones farmaceuticas.
MY124786A (en) Bis-arylsulfones
WO2002018379A3 (en) 7-oxo pyridopyrimidines
GB9907571D0 (en) Compounds
BG108164A (en) Glyt-1 inhibitors
ZA200400824B (en) Pyridin-2-yl-methlyamine derivatives for treating opioid dependence.
MXPA04001001A (es) PRAMIPEXOL PARA EL TRATAMIENTO DEL TRASTORNO DE HIPERACTIVIDAD Y DeFICIT DE LA ATENCION.
MY139844A (en) 1,2,4-triaminobenzene derivatives and their uses thereof for the prevention, treatment and/or inhibition of disorders of the central nervous system